Portal vein embolization with N-butyl cyanoacrylate glue is superior to other materials: a systematic review and meta-analysis
Authors:
- 26 January 2021
- journal article
- review article
- Published by Springer Nature in European Radiology
- Vol. 31 (8) , 5464-5478
Abstract
Objectives It remains uncertain which embolization material is best for portal vein embolization (PVE). We investigated the various materials for effectiveness in inducing future liver remnant (FLR) hypertrophy, technical and growth success rates, and complication and resection rates. Methods A systematic review from 1998 to 2019 on embolization materials for PVE was performed on Pubmed, Embase, and Cochrane. FLR growth between the two most commonly used materials was compared in a random effects meta-analysis. In a separate analysis using local data (n = 52), n-butyl cyanoacrylate (NBCA) was compared with microparticles regarding costs, radiation dose, and procedure time. Results In total, 2896 patients, 61.0 ± 4.0 years of age and 65% male, from 51 papers were included in the analysis. In 61% of the patients, either NBCA or microparticles were used for embolization. The remaining were treated with ethanol, gelfoam, or sclerosing agents. The FLR growth with NBCA was 49.1% ± 29.7 compared to 42.2% ± 40 with microparticles (p = 0.037). The growth success rate with NBCA vs microparticles was 95.3% vs 90.7% respectively (p < 0.001). There were no differences in major complications between NBCA and microparticles. In the local analysis, NBCA (n = 41) entailed shorter procedure time and reduced fluoroscopy time (p < 0.001), lower radiation exposure (p < 0.01), and lower material costs (p < 0.0001) than microparticles (n = 11). Conclusion PVE with NBCA seems to be the best choice when combining growth of the FLR, procedure time, radiation exposure, and costs. Key Points • The meta-analysis shows that n-butyl cyanoacrylate (NBCA) is superior to microparticles regarding hypertrophy of the future liver remnant, 49.1% ± 29.7 vs 42.2% ± 40.0 (p = 0.037). • There is no significant difference in major complication rates for portal vein embolization using NBCA, 4% (24/681), compared with microparticles, 5% (25/494) (p > 0.05). • Local data shows a shorter procedure time, 215 vs 348 mins from arrival to departure at the interventional radiology unit, and fluoroscopy time, 43 vs 96 mins (p < 0.001), lower radiation dosage, 573 vs 1287 Gycm 2 (p < 0.01), and costs, €816 vs €4233 (p < 0.0001) for NBCA compared to microparticles.Keywords
This publication has 84 references indexed in Scilit:
- Portal Vein Embolization before Right Hepatectomy: Improved Results Using n-Butyl-Cyanoacrylate Compared to Microparticles Plus CoilsCardioVascular and Interventional Radiology, 2013
- Portal Vein Embolization Before Liver Resection: A Systematic ReviewCardioVascular and Interventional Radiology, 2012
- Safety and efficacy of preoperative right portal vein embolization in patients at risk for postoperative liver failure following major right hepatectomyHPB, 2012
- Predictive Factors for Hypertrophy of the Future Remnant Liver After Selective Portal Vein EmbolizationAnnals of Surgical Oncology, 2010
- Quality Improvement for Portal Vein EmbolizationCardioVascular and Interventional Radiology, 2010
- Volumetric and Functional Recovery of the Remnant Liver After Major Liver Resection with Prior Portal Vein EmbolizationJournal of Gastrointestinal Surgery, 2009
- Hypertrophy of the non-embolized liver after chemotherapyHPB, 2009
- Remnant liver regeneration after two-stage hepatectomy for multiple bilobar colorectal metastasesEuropean Journal of Surgical Oncology, 2007
- Classification of Surgical ComplicationsAnnals of Surgery, 2004
- Percutaneous Portal Vein Embolization Increases the Feasibility and Safety of Major Liver Resection for Hepatocellular Carcinoma in Injured LiverAnnals of Surgery, 2000